NASDAQ:CELU Celularity (CELU) Stock Price, News & Analysis $0.61 -0.02 (-3.19%) As of 02:14 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Celularity Stock (NASDAQ:CELU) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Celularity alerts:Sign Up Key Stats Today's Range$0.60▼$0.6350-Day Range$0.63▼$1.7152-Week Range$0.56▼$2.55Volume75,655 shsAverage Volume1.24 million shsMarket Capitalization$19.80 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Celularity is a biotechnology company that develops cell therapies and other products derived from the human placenta. Its platform uses cells collected after childbirth, which the company processes for potential use in regenerative medicine and treatment of disease. The company’s research includes placental-derived natural killer cells and other cell types being developed for potential applications in cancer and other conditions. Its pipeline has included candidates such as CYNK-001, an investigational natural killer cell therapy. Founded in 2016, Celularity is headquartered in Florham Park, New Jersey. Its work focuses on developing and manufacturing placenta-derived products for clinical and commercial use.AI Generated. May Contain Errors. Read More Celularity Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks7th Percentile Overall ScoreCELU MarketRank™: 0.365853658535 of 5 starsCelularity scored higher than 7% of companies evaluated by MarketBeat, and ranked 865th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingCelularity has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageCelularity has only been the subject of 1 research reports in the past 90 days.Read more about Celularity's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Celularity is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Celularity is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.99% of the float of Celularity has been sold short.Short Interest Ratio / Days to CoverCelularity has a short interest ratio ("days to cover") of 2.33, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Celularity has recently increased by 21.05%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCelularity does not currently pay a dividend.Dividend GrowthCelularity does not have a long track record of dividend growth. News and Social Media2.4 / 5News SentimentN/A News SentimentCelularity has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Celularity this week, compared to 2 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Celularity insiders have not sold or bought any company stock.Percentage Held by Insiders17.30% of the stock of Celularity is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions19.02% of the stock of Celularity is held by institutions.Read more about Celularity's insider trading history. Receive CELU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celularity and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CELU Stock News HeadlinesHead-To-Head Review: Celularity (NASDAQ:CELU) versus Upstream Bio (NASDAQ:UPB)November 7, 2026 | americanbankingnews.comCelularity, Vesalius announce peptide API manufacturing pact in Florham ParkOctober 31, 2026 | roi-nj.comRWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.November 16 at 1:00 AM | Porter & Company (Ad)Celularity Inc. announces exclusive peptide API manufacturing collaboration with Vesalius Longevity Labs on October 29, 2026October 29, 2026 | msn.comCelularity and Vesalius Longevity Labs Sign Exclusive Collaboration for Peptual® Peptide APIs Manufactured in the United StatesOctober 29, 2026 | finance.yahoo.comCelularity Regains Compliance with Nasdaq Periodic Reporting RequirementOctober 22, 2026 | globenewswire.comCelularity Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026October 21, 2026 | marketscreener.comMViome CEO Jain to join board of directors at Florham Park-based CelularityOctober 1, 2026 | roi-nj.comRSee More Headlines CELU Stock Analysis - Frequently Asked Questions How have CELU shares performed this year? Celularity's stock was trading at $1.11 at the start of the year. Since then, CELU shares have decreased by 45.6% and is now trading at $0.6040. How were Celularity's earnings last quarter? Celularity, Inc. (NASDAQ:CELU) posted its quarterly earnings data on Tuesday, October, 20th. The company reported $0.02 earnings per share for the quarter. The company had revenue of $5.43 million for the quarter. When did Celularity's stock split? Celularity's stock reverse split on the morning of Thursday, February 29th 2024.The 1-10 reverse split was announced on Thursday, February 29th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 29th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Celularity's major shareholders? Top institutional shareholders of Celularity include State Street Corp (0.18%). View institutional ownership trends. How do I buy shares of Celularity? Shares of CELU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Celularity own? Based on aggregate information from My MarketBeat watchlists, some other companies that Celularity investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Recursion Pharmaceuticals (RXRX), Tesla (TSLA), Beam Therapeutics (BEAM), Ginkgo Bioworks (DNA) and Altimmune (ALT). Company Calendar Last Earnings10/20/2026Today11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 3 weeks, CELU's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CELU CIK1752828 Webwww.celularity.com Phone908-768-2170FaxN/AEmployees115Year Founded2016Profitability EPS (Trailing Twelve Months)($1.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$91.72 million Net Margins-246.65% Pretax Margin-245.66% Return on EquityN/A Return on Assets-48.20% Debt Debt-to-Equity RatioN/A Current Ratio0.11 Quick Ratio0.10 Sales & Book Value Annual Sales$18.67 million Price / Sales1.04 Cash FlowN/A Price / Cash FlowN/A Book Value($1.32) per share Price / Book-0.46Miscellaneous Outstanding Shares32,451,000Free Float15,284,000Market Cap$19.50 million OptionableOptionable Beta0.88 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:CELU) was last updated on 11/16/2026 by MarketBeat.com Staff. From Our PartnersMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment t...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredA Nasdaq drone company just landed a deal with a Philippine billionaire's groupA Nasdaq-listed drone company just signed an exclusive agreement with Prime Strategic Holdings, part of billio...The Tomorrow Investor | SponsoredBuy Stocks… A Crash is ComingThink stocks are expensive and a crash is coming? Economist Jim Rickards says you're right, but he urges inves...Paradigm Press | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celularity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celularity With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.